ArticleCJC open2026
Tricuspid Transcatheter-Edge-to-Edge-Repair and Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation: Patient Profiles and Outcomes.
Article in CJC open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter tricuspid valve replacement (TTVR) is typically reserved for patients in whom tricuspid valve transcatheter edge-to-edge repair (T-TEER) is deemed unsuitable or unlikely to provide effective treatment. Comparative data evaluating patient profiles, disease stage, and outcomes between T-TEER and TTVR are limited. We aimed to analyze and compare patient profiles, selection, and outcomes with either T-TEER or TTVR. Methods: A total of 43 consecutive patients from May 2018 to April 2023 were retrospectively divided into 2 groups: Group-1 underwent T-TEER; and Group-2 underwent TTVR. Primary endpoints are as follows: inpatient mortality; and 30-day and 12-month mortality. Secondary endpoints are as follows: echocardiographic tricuspid regurgitationgrading; new pacemaker implantation; and heart failure-related readmissions at 30 days and 12 months. Results: A total of 43 patients underwent intervention (T-TEER, n = 14; TTVR, n = 29;). The mean age was 77.6 ± 10.3 years, and 38 patients (88%) were diagnosed with functional tricuspid regurgitation. The in-hospital mortality rate was 7%; the 30-day mortality rate was 12% with heart failure readmission for 14%.The 12-month mortality rate was 33%, with heart failure readmission for 37%. No in-hospital or 30-day mortality occurred in the T-TEER group. The 12-month mortality rate was 29% in the T-TEER group vs 34% in the TTVR group. The TTVR cohort showed numerically younger patients (76.2 ± 10.6 vs 80.4 ± 9.6 years, Conclusions: Our findings suggest that patients undergoing T-TEER vs TTVR may represent different disease stages. Further data are required to determine the best patient selection for T-TEER vs TTVR to optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.